Denosumab—a new option for solid tumors metastatic to bone
Author:
- 10 May 2011
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 8 (6) , 322-324
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaJournal of Clinical Oncology, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- RANK ligand as a therapeutic target for bone metastases and multiple myelomaCancer Treatment Reviews, 2008
- OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone MetabolismAnnual Review of Immunology, 2006
- A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.Clinical Cancer Research, 2006
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004